N/A N=10 Skin to Skin and Heart Rate Variability
Heart Rate Variability · Preterm Infant
Primary: Heart Rate Variability — 9.68 ms
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=333 Life Care Specialists (LCS) With a Focus on Patient Pain Management and Prevention of Substance Misuse
Opioid Use
Primary: Numeric Rating Scale Average Pain Score — 7.62; 7.94; 8.43; 5.88 units on a scale
N/A N=11 Measuring Fatty Acid Oxidation in Gliomas Using 18F-FPIA PET/MRI
Glioma
Primary: Quantitative Measurement of [18F]-FPIA Uptake in Human Gliomas — 0.9041; 1.3529; 2.0470 SUV60_max
N/A N=30 EXPLORER PET/CT in Healthy Volunteers
Healthy
Primary: Standardized Uptake Value SUV(t)= C(t)/ID/BW; C(t) is Radioactivity Measured at the Time t, Decay Corrected to t=0 and Converted From a Volume to a Mass Based Unit Via…
Phase 2 N=89 2-Hydroxybenzylamine (2-HOBA) to Prevent Early Recurrence of Atrial Fibrillation After Catheter-based Ablation
Atrial Fibrillation
Primary: Number of Patients Atrial Fibrillation — 26; 14 Participants
Phase 2 N=26 Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN
Head and Neck Squamous Cell Carcinoma · Head and Neck Cancer · Head and Neck Cancer Metastatic
Primary: Safety as Measured by Number of Participants With Drug-related Adverse Events — 19; 2 Participants
Phase 2 N=272 A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults
Coronavirus Disease 2019 (COVID-19)
Primary: Adverse Events of Special Interest — 0; 0 Participants
N/A N=86 Novapak Prospective Observational Clinical Trial
Nasal Airway Obstruction
Primary: Safety Assessment - Adverse Events Related to Device — 0; 1; 2; 59 Adverse Events
N/A N=90 Performance, Safety and Efficacy of NPWT Device
Wound Healing and Prevention
Primary: Negative Pressure Maintenance at Nominal 80 mmHg — -71.5; -56.0 millimeters of mercury (mmHg)
Phase 2 N=155 Safety and Efficacy Study of VIS649 for IgA Nephropathy
Immunoglobulin A Nephropathy · Glomerular Disease · IgAN
Primary: Number of Participants With Adverse Events Graded by Severity — 19; 22; 22; 23 Participants
N/A N=117 Yoga and Physical Activity for Veterans
PTSD
Primary: Clinician Administered PTSD Scale for Diagnostic and Statistical Manual Version 5 (CAPS-5) — 3.92; 3.46 change in units on a scale — p=0.74
Phase 2 N=980 Twitter-enabled Mobile Messaging for Smoking Relapse Prevention (Tweet2Quit)
Smoking Cessation
Primary: Percentage of Participants With a 6-month Sustained Abstinence — 23; 45; 18 Participants — p=.779
N/A N=1,855 The Colorectal Breath Analysis (COBRA) Study
Colorectal Cancer · Colorectal Polyps · Colorectal Adenocarcinoma
Primary: Determine the Diagnostic Accuracy of the Proposed Breath Test for Detection of Colorectal Cancer in All Patients — 79; 86 percentage of true cases
N/A N=99,314 Screening for Stomach Diseases and Colorectal Neoplasms With the Fecal Testing
Colorectal Cancer · Stomach Disease
Primary: Incidence of Stomach Cancer — 49; 59 Participants
Phase 2 N=43 A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)
Wet Macular Degeneration
Primary: SRD-part: Number of Participants With Ocular Dose Limiting Events (DLEs) — 0; 0; 0; 0 Participants